Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | LGALS3 | P17931 | 3/20 | 0.44 |
| ▸ | LGALS9 | O00182 | 2/20 | 0.44 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.44 |
| ▸ | LGALS7; LGALS7B | P47929 | 2/20 | 0.44 |
| ▸ | ANTXR2 | P58335 | 1/20 | 0.40 |
| ▸ | SELP | P16109 | 4/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.38 |
| ▸ | SELE | P16581 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12454166 | 0.96 | LGALS3 (0.47) | MAOBLGALS3LGALS9LGALS1LGALS7; LGALS7B | |
| SCHEMBL14685786 | 0.96 | LGALS3 (0.47) | MAOBLGALS3LGALS9LGALS1LGALS7; LGALS7B | |
| SCHEMBL15473995 | 0.96 | LGALS3 (0.47) | MAOBLGALS3LGALS9LGALS1LGALS7; LGALS7B | |
| SCHEMBL15966260 | 0.95 | ANTXR2 (0.42) | MAOBLGALS3LGALS9LGALS1LGALS7; LGALS7B | |
| SCHEMBL15966235 | 0.90 | ANTXR2 (0.40) | MAOBANTXR2SELPPTPN1MAPK1 | |
| SCHEMBL16258134 | 0.89 | PTPN1 (0.42) | LGALS3LGALS9LGALS1LGALS7; LGALS7BANTXR2 | |
| SCHEMBL15966246 | 0.88 | MAOB (0.42) | MAOBLGALS3LGALS9LGALS1LGALS7; LGALS7B | |
| SCHEMBL15966236 | 0.87 | LGALS3 (0.41) | MAOBLGALS3LGALS9LGALS1LGALS7; LGALS7B | |
| SCHEMBL15952812 | 0.86 | LGALS3 (0.46) | MAOBLGALS3LGALS9LGALS1LGALS7; LGALS7B | |
| SCHEMBL15952811 | 0.86 | LGALS3 (0.46) | MAOBLGALS3LGALS9LGALS1LGALS7; LGALS7B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140235850-A1 | SYNTHESIS OF HMO CORE STRUCTURES | GLYCOM A/S (DK) | 2014-08-21 | — | — | US | disclosed |
| WO-2013044928-A1 | SYNTHESIS OF HMO CORE STRUCTURES | GLYCOM A/S (DK) | 2013-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235850-A1 | SYNTHESIS OF HMO CORE STRUCTURES | GNE, OGT, GALE | MAOB 297/4885LGALS3 165/4885LGALS9 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.